# Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease

> **NCT01568645** · PHASE1 · WITHDRAWN · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)**

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Carvedilol
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT01568645
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-03-02
- **Primary completion:** 2012-12-11
- **Final completion:** 2012-12-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568645, "Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01568645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*